PRDX3 and melanoma: In addition to previously reported serum autoantibodies, including IRBP, CAII, and bestrophin in patients with paraneoplastic vitelliform retinopathy [10,13,14], peroxiredoxin 3 (PRDX3) is identified as a new putative antigen in RPE attacked by autoantibodies in a melanoma patient with paraneoplastic vitelliform maculopathy [12].